Global report - June 29, 2019
Fujifilm constructs new cell culture media manufacturing site in Europe
The company has announced plans to open a third manufacturing facility located in Tilburg, Netherlands. The company currently has sites in the United States and Japan. Fujifilm’s investment in this project demonstrates its commitment to accelerate development in bioproduction and, cell and gene therapy markets, it states. The biopharmaceutical market is growing at a high […]
Global report - March 27, 2019
EU parliament has voted to end daylight saving time
The European Parliament has voted to end daylight saving time in EU member states. The biannual clock changes will come to an end in 2021 when individual member states will be able to decide whether they will remain on winter time or summer time permanently. The EU first started investigating ending the practice of daylight […]
Global report - February 21, 2019
In focus – U.S. drug prices
The stories have been in the U.S. media over and over in the past few years - the cost of a life-saving or maintenance drug suddenly jumps by as much as 1 000 percent, leaving patients and their advocates angry and bewildered.
Global report - February 6, 2019
GSK acquires Merck’s cancer immunotherapy for up to €3.7 billion
GlaxoSmithKline (GSK) and Merck have entered into a global strategic alliance to jointly develop and commercialise M7824, an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers. This includes a Phase II trial to investigate M7824 compared with pembrolizumab as a first-line treatment in patients […]
Acquisition - January 6, 2019
BMS acquires Celgene for $74 billion
Bristol-Myers Squibb (BMS) and Celgene have announced that they have entered into a definitive merger agreement under which BMS will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for […]
Global report - January 1, 2019
Q&A: Nikolaj Sørensen on U.S. drug pricing
Nordic Life Science asked Nikolaj Sørensen, CEO of Orexo, about his opinion on the ongoing U.S. drug pricing debate. Sørensen said that historically U.S. drug pricing has been recognized to be much more attractive than European drug pricing. And this is still the truth for pharmaceuticals without competition, which has led to some of the obscene […]
